Fernholm R, Thoren M, Hoybye C, Anderstam B, Pernow Y, Saaf M, Hall K
Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Solna and Karolinska Institute, Stockholm, Sweden.
Growth Horm IGF Res. 2009 Jun;19(3):206-11. doi: 10.1016/j.ghir.2008.09.001. Epub 2008 Nov 6.
GH replacement to growth hormone deficient (GHD) adults improves body composition. In a subset however, lean body mass (LBM) fails to increase despite normalization of IGF-I and amino acid availability could be of importance. We analyzed amino acid (AA) profiles in plasma and erythrocytes (RBC) and associations with LBM, serum IGF-I and IGFBP-1 before and during GH replacement.
Examinations were performed in 15 GHD patients (six women), aged 34-61 yrs before and after 12 months of GH therapy and in a control group of 20 healthy males aged 31-68 yrs. LBM was measured by dual energy X-ray absorptiometry (DXA), free AAs in plasma and RBC by high performance liquid chromatography and serum IGF-I and IGFBP-1 by in-house RIAs.
Tertiary care referral centre.
At baseline, female GHD patients tended to have lower concentrations of the essential branched - chain AAs isoleucine and leucine, total essential AAs, and of the non-essential AA glutamine than the male patients. Male GHD patients tended to have higher plasma and RBC glutamate than controls. At 12 months, IGF-I had normalized in all but one patient and mean LBM gain was 1.9+/-0.4 kg. AA levels were unchanged. The change in LBM at 12 months was positively correlated to the ratio between the sum of isoleucine, leucine and valine and baseline LBM kg/m(2) (r=0.76, p=0.001, n=15).
Our results suggest that the essential branched-chain amino acids in plasma are important for the LBM response to GH substitution. Our finding has to be confirmed in larger groups of GHD adults before making a proper selection of AAs to be measured in plasma and added as dietary supplement during GH therapy. GH administration did not change AA levels and measurements are not useful for monitoring of GH therapy at the time being.
对生长激素缺乏(GHD)的成年人进行生长激素替代治疗可改善身体成分。然而,在一部分患者中,尽管胰岛素样生长因子-I(IGF-I)恢复正常,但瘦体重(LBM)仍未增加,氨基酸可用性可能起重要作用。我们分析了生长激素替代治疗前后血浆和红细胞(RBC)中的氨基酸(AA)谱及其与LBM、血清IGF-I和IGFBP-1的相关性。
对15例GHD患者(6名女性)进行检查,年龄在34 - 61岁,在生长激素治疗12个月前后进行,同时选取20名年龄在31 - 68岁的健康男性作为对照组。通过双能X线吸收法(DXA)测量LBM,采用高效液相色谱法测定血浆和RBC中的游离AA,采用内部放射免疫分析法测定血清IGF-I和IGFBP-1。
三级医疗转诊中心。
基线时,女性GHD患者的必需支链氨基酸异亮氨酸和亮氨酸、总必需氨基酸以及非必需氨基酸谷氨酰胺的浓度往往低于男性患者。男性GHD患者的血浆和RBC谷氨酸含量往往高于对照组。12个月时,除1例患者外,所有患者的IGF-I均恢复正常,平均LBM增加1.9±0.4 kg。AA水平未发生变化。12个月时LBM的变化与异亮氨酸、亮氨酸和缬氨酸之和与基线LBM kg/m²的比值呈正相关(r = 0.76,p = 0.001,n = 15)。
我们的结果表明,血浆中的必需支链氨基酸对LBM对生长激素替代治疗的反应很重要。在对血浆中要测量的AA进行适当选择并在生长激素治疗期间作为膳食补充剂添加之前,我们的发现必须在更大规模的GHD成年人群中得到证实。生长激素给药并未改变AA水平,目前测量AA对监测生长激素治疗并无用处。